November 9, 2016 5:09pm
… Positive reaction in “our” universe reflects the notions that election results have not changed the fundamentals of the sector
Will this upside further pricing opportunity?
I answer one question; in which company should investors put, keep and commit their money!
Pre-open indication’s tally: 1 hit (AGTC) and 1 miss (BSTG)
Lose an advantage or be a subscriber! Today’s results have implications to Thursday's sector activity.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. stocks surged more than 1% Wednesday with financials and health care leading after Republican Donald Trump won the presidential election, defying market expectations for a Hillary Clinton win.
The NASDAQ closed +57.558 or +1.11% to 5,251.07 and the DOW closed UP +256.95 or +1.40% to 18,589.69.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 27/13 and 3 flats – the opposite of yesterday;
- The mid-day stayed positive with an A/DL of 34/9 and 0 flat;
- The closing bell was negative with A/DL of 34/8 and 1 flat;
Henry’omics:
U.S. equities rose Wednesday after a stunning victory by Republican Donald Trump over Hillary Clinton sent markets for a wild ride.
- The day's rally took the major averages within … 2% of their all-time intraday highs, and marked a stunning recovery from a sharp plunge in stock index futures overnight.
The S&P 500 traded +1% higher as the NASDAQ composite rose about 0.09%.
- The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded 16.9% lower, near 15.6.
The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened positive, stayed positive at the mid-day and closed positive.
From this morning’s shareholder letter, “It ain’t over, till it’s done as we are in a wait and see mode!”
By the mid-day, the Dow rose about 200 points before holding about 140 points higher, with Applied Genetic Technologies (AGTC +$2.10) and Adverum (ADVM +$0.40) contributing the most gains.
The biggest losers of the morning session were Histogenics (HSGX -$0.10), Capricor (CAPR -$0.07), Vericel (VCEL -$0.05) and Cesca Therapeutics (KOOL -$0.05).
The iShares Russell 2000 (IWM) indicated a negative pre- open of -1.54% and closed UP +3.06% while the iShares Nasdaq Biotechnology (IBB) indicate a pre-open positive of +3.62% and closed UP +8.93%.
These daily downside swings show just how “soft” pricing was and is last and this week to date. Look close at today and the past days – trading ranges:
The downside trend reflects a pricing trend range of:
- Wednesday decliners ranged from -0.53% <CLBS> to -8.35% <FCSC> in 8 equities;
- Tuesday’s decliners ranged from -0.02% <OPXA> to -5.63% <KOOL> in 23 equities;
- Monday’s decline ranged from -0.08% to -14.94% in 13 equities;
- Friday’s decline ranged from -0.53% to -6.40% in 8 equities;
- Thursday’s decline ranged from -0.24% to -13.74% in 37 equities;
- Last Wednesday’s decline ranged from -0.01% to -20.41% in 36 equities;
The upside shows a pricing trend range of:
- Wednesday’s advancers ranged from +1.06% <VTGN> to +29.79% <AGTC> in 34 equities;
- Tuesday’s advancers ranged from +0.35% <ONVO> to +23.63% <OSIR> in 18 equities;
- Monday’s advancers ranged from +1.03% to +10.41% in 25 equities;
- Friday’s advances ranged from +0.01% to +11.06% in 31 equities;
- Thursday’s advances ranged from +1.62% to +4.66% in 5 equities;
- Last Wednesday’s advances ranged from +0.24% to +7.03% in 6 equities;
Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers. The shifting correlation of the number of equites inclining versus the decliners hasn’t abated!
Wednesday’s 34 gainers as compared to Tuesday’s 18 compared to Monday‘s 25 compared to Friday’s 31 from Thursday’s gains of 5 declined from last Wednesday’s 6 …
While Wednesday’s 8 decliners compared to Tuesday’s 24 following Monday’s 13 compared to Friday’s decliners to 8 compared to Thursday’s 37 post last Wednesday’s 36 decliners...
Pre-open indication’s tally: 1 hit (AGTC) and 1 miss (BSTG)
- Applied Genetic Technologies (AGTC) closed UP +$2.10 – hit;
- Biostage (BSTG) closed UP +$0.04 – miss;
Percentage decliners:
- Fibrocell (FCSC) -8.35% after Tuesday’s -4.76% after Monday’s -5.96%;
- ImmunoCellular (NYSEMKT: IMUC) -6.28% after Tuesday’s +9.18% or +$0.0079;
- Histogenics (HSGX) -3.94% after Tuesday’s +9.96%;
- Capricor (CAPR) -2.44%;
- Vericel (VCEL) -2.38% after Tuesday’s -4.55%;
Percentage advancers:
- Applied Genetic Technologies (AGTC) +29.79%;
- Sangamo (SGMO) +17.91% after Tuesday’s -4.29%;
- Aduro Biotech (ADRO) +14.74%;
- bluebird bio (BLUE) +13.99%;
- Adverum (ADVM) +13.79%;
Flat:
- Neuralstem (CUR) at $0.24;
Review my fear gauge or the CBOE Volatility Index (VIX):
· Wednesday traded near 15.6;
· Tuesday traded near 18.5;
· Monday traded near 18.6
· Friday traded near 22.5;
· Thursday traded near 22.47;
· Last Wednesday traded near 19.4;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
